Black triangle (pharmacovigilance)

Black triangle

Black triangle

Black Triangle Scheme in the United Kingdom

The Black Triangle Scheme in the United Kingdom is a regulatory measure applied to certain medications and vaccines to signify that they are new to the market or that an existing medication or vaccine is being used for a new indication or via a new route of administration. This symbol, a black triangle (▼), serves as an important marker for healthcare professionals and patients, indicating the need for heightened surveillance and reporting of any Adverse Drug Reactions (ADRs) associated with these treatments.

Introduction

When a medication or vaccine is introduced to the market or repurposed for a new use, its comprehensive safety profile is not fully established despite rigorous pre-approval testing. The Black Triangle Scheme, overseen by the Medicines and Healthcare products Regulatory Agency (MHRA), plays a crucial role in the continued evaluation of the medication's safety by encouraging the reporting of all suspected ADRs, no matter how minor they may seem.

Examples and Significance

Examples of how the black triangle might appear include:

• NewDrugTradeName^▼
• NewDrugTradeName▼

The presence of the black triangle emphasizes the responsibility of healthcare professionals and patients to report any observed ADRs. This active post-marketing surveillance helps gather valuable data on the medication's safety in real-world use, contributing to a deeper understanding of its risk-benefit profile.

Reporting Adverse Drug Reactions

The MHRA encourages the voluntary reporting of ADRs through the Yellow Card Scheme. This system allows healthcare professionals, patients, and caregivers to contribute to the safety monitoring of medications, ensuring that potential risks are identified and managed promptly.

Duration of the Black Triangle Label

A medication or vaccine under the Black Triangle Scheme is subject to this additional monitoring for at least two years following its market introduction. After this period, the status is reviewed by regulatory authorities, and the black triangle designation may be removed based on the accumulated safety data and understanding of the medication's risk profile.

Impact and Importance

The Black Triangle Scheme represents a critical component of the UK's Pharmacovigilance efforts, ensuring that new medications and vaccines are used safely and effectively across the population. It underscores the dynamic nature of medication safety, acknowledging that the full spectrum of potential ADRs can only be revealed through widespread use and diligent reporting.

References

• Medicines and Healthcare products Regulatory Agency (MHRA) website sections on the Black Triangle Scheme and related topics.

Further Reading

• British National Formulary for additional details on specific medications under the scheme.

See Also

• Pharmacovigilance for the broader field of drug safety monitoring.
• EudraVigilance, the European system for monitoring the safety of medicinal products.
• Uppsala Monitoring Centre, the World Health Organization’s center for international drug monitoring.